Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Expert Opinion on Pharmacotherapy
Volume 24, 2023 - Issue 7
Letter to the Editor
Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis
Fiammetta Vanolia Neuroimmunology and Neuromuscular Disease Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy;b Piazzale Aldo Moro 5, Department of Human Neurosciences Sapienza University of Rome, Rome, ItalyCorrespondence[email protected]
https://orcid.org/0000-0002-9081-6462View further author information
https://orcid.org/0000-0002-9081-6462View further author information & Renato Mantegazzaa Neuroimmunology and Neuromuscular Disease Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italyhttps://orcid.org/0000-0002-9810-5737View further author information
https://orcid.org/0000-0002-9810-5737View further author information